p97

CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor ( IC50=11 nM).

NMS-873 is a potent and selective allosteric inhibitor of VCP p97.

DBEQ (JRF 12) is a selective, potent, reversible, and ATP-competitive p97 inhibitor.

ML240 is a selective, ATP-competitive p97 inhibitor.

p97-IN-1 is a potent inhibitor of p97 with an IC 50 <30 nM [1].

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

ML241 is a potent and selective inhibitors of p97 ATPase.ML241 inhibits degradation of a p97-dependent but not a p97-independent proteasome substrate in a dual-reporter cell line. ML241 may be a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway-specific p97 inhibitors.

MSC1094308 is a reversible, non-ATP-competitive alterative inhibitor targeting type II AAA ATPase (VCP p97) and type I AAA ATPase (VPS4B), which affects the intracellular protein degradation process by binding to a specific hotspot region of p97 and inhibiting D2 ATPase activity.

UP158 enhances ATPase activity and stimulates valosin-containing protein (VCP), with an EC50 of 2.57 μM.

NSC819701 is a triazole-based inhibitor of p97ATPase. It inhibits the activity of p97ATPase by binding to specific sites on p97.

NSC799462, a triazole inhibitor, specifically targets p97 ATPase, exerting its effect by binding to a designated site on the p97 enzyme. This interaction induces localized structural alterations in p97, effectively inhibiting its ATPase activity with an IC 50 value of 15 nM.

UP163 enhances ATPase activity and activates valosin-containing protein (VCP), with an EC50 of 9.0 μM. It also reduces MG-132-induced TDP-43 aggregation.

ML241 is a potent and selective inhibitors of p97 ATPase.

UP12 enhances ATPase activity by activating valosin-containing protein (VCP), with an EC50 of 2.57 μM.

UPCDC30766, a potent allosteric inhibitor of p97, exhibits an IC50 of 12 nM and is applicable for colon cancer research [1].